← Back to patent-cliff list
Epinephrine intranasal spray (ARS Pharmaceuticals)
Tier C — Watch / tradeEpinephrine intranasal spray (ARS Pharmaceuticals)
ARS Pharmaceuticals Inc
Originator
2024
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：β-adrenoceptors, α-adrenoceptors
Brand：Neffy, EUR neffy, EURneffy
Indications (approved)：Allergic reaction
Regional status
US
Approved
2024-08-09
EU
Approved
2024-06-28
China
Approved
2025-12-22
Japan
Approved
2025-09-19
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Epinephrine intranasal spray (ARS Pharmaceuticals)?
Approved indications include: Allergic reaction.
When does the Epinephrine intranasal spray (ARS Pharmaceuticals) patent expire?
No public expiry year is available for Epinephrine intranasal spray (ARS Pharmaceuticals) yet; this page updates once verified.
How do I get a quote for Epinephrine intranasal spray (ARS Pharmaceuticals) intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-09-27